Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elacestrant + triptorelin
- Development stage
- Unknown
- Lead developer
- Menarini
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
Elacestrant + triptorelin is a combination therapy under investigation for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer in premenopausal women. Elacestrant is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor (ER), thereby blocking estrogen-driven tumor growth. Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses ovarian function by downregulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced production of endogenous estrogens. The combination aims to maximize endocrine suppression in premenopausal patients by pairing direct ER degradation with ovarian function suppression. This regimen is being evaluated in clinical trials such as the PREMIERE study for its biological effects and efficacy compared to elacestrant alone[5][7].
- Brand names
- DipherelinPamorelin
- Other names
- elacestrant + triptorelin
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)ESR1 (ERα)
Beyond the preview
Go deeper on elacestrant + triptorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elacestrant + triptorelin.